Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway

被引:42
作者
del Rincón, SV
Rousseau, C
Samanta, R
Miller, WH
机构
[1] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
retinoic acid; IRS-1; IGF; AKT; breast cancer;
D O I
10.1038/sj.onc.1206485
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the MCF-7 breast cancer cell line, insulin-like growth factors (IGFs) are known to elicit antiproliferative actions via the insulin receptor substrate-1 (IRS-1)/PI 3-kinase/AKT pathway. All-trans retinoic acid (RA) is a potent inhibitor of MCF-7 cell proliferation, but the mechanism by which growth regulation is achieved remains unclear. We investigated the effects of RA on the regulation of the IGF-IR and its key signaling elements: IRS-1, IRS-2, and SHC. Treatment of MCF-7 cells with RA caused a significant reduction in IRS-1 protein and tyrosine phosphorylation levels at a concentration and time consistent with RA-mediated growth inhibition. IRS-1 regulation is selective, as RA did not influence IRS-2 or SHC levels. Downstream signaling events were also selectively reduced, as RA abrogated IGF-I-stimulated AKT activation but did not alter erk1/2 activation. To confirm the importance of IRS-1 regulation by RA, we examined the response to RA in MCF-7 cells overexpressing IGF-IR and IRS-1. RA resistance was observed in MCF-7 cells overexpressing IRS-I but not IGF-IR. This suggests that RA-mediated growth inhibition requires the selective downregulation of IRS-1 and AKT. Therapeutic agents targeting the IRS-1/PI 3-kinase/AKT pathway may enhance the cytostatic effects of RA in breast cancer, since overexpression of IRS-1 and AKT have been reported in primary breast tumors.
引用
收藏
页码:3353 / 3360
页数:8
相关论文
共 75 条
[1]   Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines [J].
Agadir, A ;
Chen, GQ ;
Bost, F ;
Li, Y ;
Mercola, D ;
Zhang, XK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (42) :29779-29785
[2]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[3]   Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].
Allen, LF ;
Lenehan, PF ;
Eiseman, IA ;
Elliott, WL ;
Fry, DW .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21
[4]   Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells [J].
Ando, S ;
Panno, ML ;
Salerno, M ;
Sisci, D ;
Mauro, L ;
Lanzino, M ;
Surmacz, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 253 (02) :315-319
[5]  
ANZANO MA, 1994, CANCER RES, V54, P4614
[6]   INSULIN-LIKE GROWTH-FACTOR-I STIMULATES TYROSINE PHOSPHORYLATION OF ENDOGENOUS C-CRK [J].
BEITNERJOHNSON, D ;
LEROITH, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (10) :5187-5190
[7]   Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor [J].
Blakesley, VA ;
Kalebic, T ;
Helman, LJ ;
Stannard, B ;
Faria, TN ;
Roberts, CT ;
LeRoith, D .
ENDOCRINOLOGY, 1996, 137 (02) :410-417
[8]  
Chang Q, 2002, CANCER RES, V62, P6035
[9]  
CULLEN KJ, 1990, CANCER RES, V50, P48
[10]  
DE LUCA LM, 1991, FASEB J, V5, P2924